FDA Seeks Comments for Draft Guidance Regarding Expedited Access for Premarket Approval of Medical Devices Intended for Unmet Medical Needs for Life Threatening or Irreversibly Debilitating Diseases or Conditions

by Saul Ewing LLP
Contact

Summary

The Food and Drug Administration (FDA) released a draft guidance on April 23, 2014 titled Expedited Access for Premarket Approval [of] Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions - Draft Guidance for Industry and Food and Drug Administration Staff 1 and is accepting comments through July 22, 2014.2  In the draft guidance, the FDA proposes the Expedited Access PMA Program (the “EAP Program”), which is a voluntary program intended to expedite Premarket Approval of medical devices that address unmet medical needs for “life threatening or irreversibly debilitating diseases or conditions.” The goal is to provide patients with more timely access to these medical devices (“EAP Devices”).

Device sponsors must request participation in the EAP Program, which is subject to FDA approval of the EAP Designation. The request should be submitted to the Agency in a Pre-Submission (“Pre-Sub”) in accordance with the Guidance for same, Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff. Generally, the sponsor should submit the Pre-Sub EAP Designation request “prior to commencement of an IDE pivotal study.” The Pre-Sub should include a “discussion of why the device meets the EAP criteria” and a Draft Development Plan, discussed below.

The following are the criteria for EAP Designation:
  1. The device is intended to treat or diagnose a life-threatening or irreversibly debilitating disease or condition.

  2. The device meets at least one of the following criteria for addressing an unmet need:

      a. The device represents a breakthrough technology that provides a clinically meaningful advantage over existing technology.

      b. No approved alternative treatment or means of diagnosis exists.

      c. The device offers significant, clinically meaningful advantages over existing approved alternatives.

      d. The availability of the device is in the best interest of patients (e.g., addresses an unmet medical need).

  3. The sponsor submits an acceptable draft Data Development Plan.

The FDA will issue written notification of its determination of whether it is granting EAP Designation. If the FDA grants the EAP Designation request, the Agency intends to provide the EAP Device sponsor with an FDA point of contact for Agency interaction.

The FDA intends to execute the EAP Program through “more interactive communications” and interactive planning and development between the EAP Device sponsor and the Agency. For example, the FDA proposes to work with sponsors to create a Data Development Plan that would detail (1) all clinical and nonclinical data required for approval, premarket, and postmarket, (2) a timeline to expedite the introduction of the device to market, and (3) proposed labeling. 

In accordance with the requirements of the Food, Drug, and Cosmetic Act (the “FDCA”), the FDA will seek the “least burdensome appropriate means of evaluating device effectiveness” to obtain device approval. The FDA anticipates accepting less certainty with regard to the benefit-risk profile of EAP Devices at the time of PMA and approving the EAP Device if data supports a “reasonable assurance of safety and effectiveness.” 

It also anticipates accepting less certainty by relying on “assessments of a device’s effect on an intermediate or surrogate endpoint that is reasonably likely to predict clinical benefit.” The FDA defines the term “intermediate endpoint” as “a measurement of clinical benefit or risk concerning a symptom or measure of function that is not the ultimate outcome of the disease.” Examples of intermediate endpoints include, but are not limited to, symptoms of hyperglycemia or angina frequency.  The FDA defines “surrogate endpoint” as “a substitute which is reasonably likely to predict clinical benefit, based on epidemiologic, therapeutic, pathophysiologic or other scientific evidence.” 

“The types of measurements which may be used as a surrogate endpoint are in vitro laboratory or medical imaging measurements, or physical signs (e.g., blood pressure measurements in trials of antihypertensive therapeutics, as a surrogate for clinical endpoints such as stroke, myocardial infarction, or mortality).” The FDA intends to utilize postmarket requirements, such as post-approval studies, to establish the more complete benefit-risk profile. Therefore, the FDA may condition the PMA of EAP Devices on postmarket requirements.

Additional conditions of PMA may include post-approval non-clinical studies, “continuing evaluation and periodic reporting on safety, effectiveness, and reliability,” and restrictive labeling that may be updated “to reflect the population and condition for which a clinical benefit was directly established in the post-approval stud(ies).”

The FDA may forgo premarket inspection of manufacturing facilities as part of the EAP Program. However, if an inspection is not conducted premarket, the Agency will conduct the inspection within the first twelve (12) months of device approval.

The FDA may revoke EAP Designation on written notice to the EAP Device sponsor if the Agency concludes any of the following:

  • The information submitted in support of a request for EAP Designation, including, without limitation, the Pre-Sub package, or any related premarket submission contained an untrue statement of material fact or omitted material information, including false statements relating to data collection; or
  • Based on evidence available, the device is no longer eligible for an EAP Designation according to the EAP criteria ….

The FDA may withdraw PMA if the Agency subsequently concludes any of the following:

  • On the basis of the data from the required post-approval study(ies), or other new information with respect to such device, evaluated together with the evidence available to FDA when the PMA application was approved, FDA finds that there is a lack of a showing of reasonable assurance that the device is safe or effective under the conditions of use 
  • prescribed, recommended or suggested in the labeling;
  • The sponsor fails to meet any post-approval requirement imposed by the PMA approval order…; or
  • On the basis of new information, evaluated together with the evidence available to FDA when the PMA was approved, FDA finds that the labeling, based on a fair evaluation of all material facts, is false or misleading … and such labeling is not corrected within a reasonable time after receipt of written notice from FDA.

Prior to withdrawing a PMA, FDA will afford an opportunity to the EAP Device sponsor to voluntarily request withdrawal.

The FDA is requesting comments to the Draft Guidance by July 22, 2014. The EAP Program will assist to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions.

* * * * *

1. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm393879.htm 
2. https://www.federalregister.gov/articles/2014/04/23/2014-09189/expedited-access-for-premarket-approval-medical-devices-intended-for-unmet-medical-need-for-life

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Saul Ewing LLP | Attorney Advertising

Written by:

Saul Ewing LLP
Contact
more
less

Saul Ewing LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!